Final Results From PAPILLON Trial Confirm Long-Term Survival in a Subset of Lung Cancer
A crossover-adjusted analysis found a significant survival benefit, while the protocol-specified final analysis did not show a clear overall survival advantage.
- On Monday, Johnson & Johnson announced final overall survival results from the Phase 3 PAPILLON study, showing RYBREVANT plus chemotherapy achieved a median overall survival of 34.3 months versus 27.9 months for chemotherapy alone.
- EGFR exon 20 insertion mutations account for approximately 12 percent of EGFR mutations and have historically been difficult to treat with targeted medicines, resulting in a five-year survival rate of just 8 percent for patients.
- Dr. Chul Kim, Director of Thoracic Oncology at MedStar Georgetown University Hospital, said the drug's bispecific design dual-targets EGFR and MET: "We've come a long way in treating EGFR exon 20 insertion-positive lung cancer."
- In the PAPILLON study, serious adverse reactions occurred in 37 percent of patients, with common side effects including rash , nail toxicity , and stomatitis , consistent with previous safety reports.
- Presented at the 2026 World Conference on Lung Cancer's Presidential Symposium, these findings represent the longest reported median overall survival in this population, establishing the regimen as a backbone therapy.
41 Articles
41 Articles
Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer
Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.
stonecountyenterprise.com
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and METResults mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8%
PAPILLON trial: Amivantamab plus chemotherapy adds months of survival in rare lung cancer
Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.
Overall Survival Benefit Not Seen with Amivantamab-Chemotherapy in Phase III PAPILLION Trial
Presenter Chul Kim, MD, MPH, said crossover from the chemotherapy arm may have contributed to the overall survival improvement failing to reach statistical significance. The post Overall Survival Benefit Not Seen with Amivantamab-Chemotherapy in Phase III PAPILLION Trial appeared first on ILCN.org (ILCN/WCLC).
Coverage Details
Bias Distribution
- 68% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
